Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.4M Buy
58,322
+4,657
+9% +$122K 0.21% 74
2026
Q1
$1.51M Sell
53,665
-1,549
-3% -$41.2K 0.27% 68
2025
Q4
$1.37M Sell
55,214
-1,518
-3% -$38.3K 0.24% 71
2025
Q3
$1.45M Sell
56,732
-6,477
-10% -$160K 0.26% 72
2025
Q2
$1.53M Buy
63,209
+1,634
+3% +$38.1K 0.3% 68
2025
Q1
$1.56M Sell
61,575
-11,150
-15% -$292K 0.34% 63
2024
Q4
$1.93M Sell
72,725
-4,440
-6% -$120K 0.41% 57
2024
Q3
$2.23M Buy
77,165
+87
+0.1% +$2.54K 0.46% 53
2024
Q2
$2.16M Buy
77,078
+1,320
+2% +$36.3K 0.48% 53
2024
Q1
$2.1M Sell
75,758
-5
-0% -$139 0.48% 54
2023
Q4
$2.18M Buy
75,763
+9,749
+15% +$295K 0.54% 50
2023
Q3
$2.19M Buy
66,014
+9,288
+16% +$328K 0.62% 47
2023
Q2
$2.08M Sell
56,726
-9,011
-14% -$351K 0.58% 48
2023
Q1
$3.37M Hold
65,737
1.02% 32
2022
Q4
$3.37M Buy
65,737
+1,258
+2% +$60.3K 1.02% 32
2022
Q3
$2.82M Sell
64,479
-1,082
-2% -$52.6K 0.93% 33
2022
Q2
$3.44M Buy
65,561
+1,232
+2% +$62.8K 1.07% 27
2022
Q1
$3.33M Buy
64,329
+9,874
+18% +$512K 0.9% 38
2021
Q4
$3.22M Buy
54,455
+9,667
+22% +$479K 0.86% 39
2021
Q3
$1.93M Buy
+44,788
New +$1.98M 0.53% 61

Other funds holding PFE

Essex LLC's PFE Position: Q2 2026 in Review

Essex LLC increased its Pfizer (PFE) stake by 8.7% in Q2 2026, buying an estimated $122K and bringing the position to 58,322 shares worth $1.4M. The position accounts for 0.21% of the portfolio, ranked #74.

Essex LLC first reported a position in PFE in Q3 2021 and has held it in 20 quarters since. The position peaked at $3.44M in Q2 2022. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Essex LLC held 58,322 shares of Pfizer worth $1.4M as of Q2 2026.
  • Essex LLC bought 4,657 Pfizer shares in Q2 2026, an estimated $122K.
  • Pfizer made up 0.21% of Essex LLC's portfolio in Q2 2026, its #74 holding.
  • Essex LLC first reported a position in Pfizer in Q3 2021 and has held it in 20 quarters since.
  • Essex LLC's Pfizer position peaked at $3.44M in Q2 2022.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Essex LLC's 13F filing for Q2 2026, filed 24 Jul 2026.